Cara Therapeutics Profit Margin

Cara Therapeutics (CARA) currently reports a profit margin of 782.87% as of March 2026. That compares with -595.39% in the prior-year period — up 231.5% year over year. That is above the Healthcare sector average of 15.29%. Use the charts on this page to explore Cara Therapeutics's profit margin history and peer comparisons.

Cara Therapeutics's profit margin increased from -595.39% to 782.87% — a 231.5% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cara Therapeutics's profit margin of 782.87% is higher than the Healthcare sector average of 15.29%. That is roughly 5019.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Cara Therapeutics's current 782.87% should be judged against Healthcare norms (sector average: 15.29%) and against CARA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 782.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Cara Therapeutics, and consider following CARA for alerts when major investors trade the stock.